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Res Syn Meth. 2018;1–18.Background: Meta‐regression results must be interpreted taking into account
the range of covariate values of the contributing studies. Results based on inter-
polation or extrapolation may be unreliable. In network meta‐regression
(NMR) models, which include covariates in network meta‐analyses, results
are estimated using direct and indirect evidence; therefore, it may be unclear
which studies and covariate values contribute to which result. We propose
graphs to help understand which trials and covariate values contribute to each
NMR result and to highlight extrapolation or interpolation.
Methods: We introduce methods to calculate the contribution that each trial
and covariate value makes to each result and compare them with existing
methods. We show how to construct graphs including a network covariate dis-
tribution diagram, covariate‐contribution plot, heat plot, contribution‐NMR
plot, and heat‐NMR plot. We demonstrate the methods using a dataset with
treatments for malaria using the covariate average age and a dataset of topical
fluoride interventions for preventing dental caries using the covariate
randomisation year.
Results: For the malaria dataset, no contributing trials had an average age
between 7–25 years and therefore results were interpolated within this range.
For the fluoride dataset, there are no contributing trials randomised between
1954–1959 for most comparisons therefore, within this range, results would
be extrapolated.
Conclusions: Even in a fully connected network, an NMR result may be esti-
mated from trials with a narrower covariate range than the range of the whole
dataset. Calculating contributions and graphically displaying them aids inter-
pretation of NMR result by highlighting extrapolated or interpolated results.
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2 DONEGAN ET AL.1 | INTRODUCTION
Network meta‐analyses have become increasingly popu-
lar in recent years in terms of application in systematic
reviews and methodological developments.1-5 Network
meta‐regression (NMR) is an extension of network meta‐
analysis, which examines whether several treatment
effects (eg, log odds ratios) differ according to a covariate
(eg, trial setting).6 For instance, if 3 treatments exist for
a particular condition (treatments 1, 2, 3), NMR could
simultaneously examine whether the treatment effect for
2 vs 1 varies according to a covariate, whether the effect
for 3 vs 1 varies according to the same covariate, and
whether the effect for 3 vs 2 also varies. NMR results from
the NMR model commonly consist of, for each compari-
son, 1 treatment effect estimated at the covariate value
zero (or at the mean covariate value when the NMR
model is centred) and 1 regression coefficient for the treat-
ment by covariate interaction.
When inconsistency (ie, variability across treatment
comparisons) or heterogeneity (ie, variability across trials
that directly compare the same 2 treatments) is detected
in a networkmeta‐analysis, the results of themeta‐analysis
may not be valid. In such cases, NMR can be used to
explore causes of the heterogeneity and/or inconsistency,
and if the variability is reduced or disappears in the
NMR, the results from the NMR may be more meaningful
than those from the network meta‐analysis and may be
used to draw reliable clinical inferences. Yet, when hetero-
geneity and/or inconsistency is still present in the NMR,
the results of the NMR may be unreliable, and it may be
more appropriate to reconsider the eligibility criteria or
explore other covariates. Moreover, NMR can be valuable
when stratified results for different patient groups are
required to answer clinical questions. For example, results
were stratified by seizure type (ie, patients suffering from
partial or generalised seizures) in a NMR of epilepsy
drugs.7,8 In these circumstances, NMR can estimate treat-
ment effects at different covariate values, facilitating strat-
ified medicine for different patient groups. For categorical
covariates (such as, surgical procedure), the treatment
effects for each category can be estimated (eg, treatment
effects for studies involving amputees and treatment
effects for studies of breast surgery). For continuous covar-
iates (eg, trial duration), it is possible to calculate treatment
effects at any value of the covariate (eg, at weeks 0, 4, 8, 12,
16, 20,....). Stratified analyses or meta‐regressions are often
used in reviews to explore patient‐level covariates (eg,
patient age) using trial‐level summaries (eg, average age)
or trial‐level covariates (eg, study location).9,10
However, when interpreting the results of a meta‐
regression, it is important to consider the covariate values
of the included trials so that interpolated or extrapolatedresults are identified. Results that rely on interpolation
or extrapolation may not be reliable and could lead to
drawing incorrect conclusions that affect clinical practice.
In a standard pair‐wise meta‐regression, where trials'
results for only 1 treatment comparison are regressed
against trials' covariate values, it is relatively simple to
identify when results are interpolated or extrapo-
lated.6,11,12 For example, if the dose of a drug ranged from
100 to 150 mg/day and 300 to 400 mg/day in the studies,
the results would be applicable for doses 100 to 150 mg/
day and 300 to 400 mg/day, but we would be less confi-
dent about applying the results (interpolated) for doses
150 to 300 mg/day, and even less confident in applying
results (extrapolated) for those over 400 mg/day. How-
ever, understanding the contribution of different covari-
ate values to results is more complicated for NMR
because results are estimated based on a combination of
direct and indirect evidence. For example, for the compar-
ison 2 vs 1, the trials that directly compare 2 vs 1 may
have covariate values for dose ranging from 100 to
200 mg/day, but the trials that contribute indirect evi-
dence (eg, 3 vs 1 and 3 vs 2) may have covariate values
ranging from 200 to 300 mg/day; therefore, the results
for that comparison may be considered to be reliably esti-
mated for doses 100 to 300 mg/day. For the comparison 3
vs 1, different trials with different covariate values may
contribute to results for that comparison, etc. Further-
more, for large treatment networks, trials that are closely
connected to a particular treatment comparison in the
network (eg, first‐order indirect evidence) may contribute
more to the NMR result for that comparison than trials
that are further away in the network (eg, third‐order indi-
rect evidence).13 Therefore, to avoid drawing misleading
conclusions in NMR, it is important to identify which tri-
als contribute to each NMR estimate, by how much they
contribute, and consider their covariate range so that each
result can be interpreted with the relevant covariate range
in mind. To our knowledge, although NMR methodology
has been widely introduced and applied, such issues
regarding interpretation have not been discussed in pub-
lished literature.6,8,14-18
In this article, we introduce novel methods to help
understand which trials and covariate values contribute
to each NMR result (ie, each treatment effect at zero
covariate and each regression coefficient) and to highlight
extrapolated or interpolated results. We propose new
methods to calculate the percentage contribution that
each trial makes to each NMR result. The methods can
tell us, for example, that a particular result is 10% based
on trials with covariate values 0 to 100 mg/day, 70% from
trials with values 100 to 200 mg/day, and 20% from trials
with values 200 to 300 mg/day. Therefore, we can con-
sider the covariate range relevant to each NMR result.
DONEGAN ET AL. 3The proposed methods to calculate contributions were
inspired by an existing fixed‐effect Frequentist method
that involved estimating the pairwise meta‐analytic treat-
ment effects based on direct evidence and calculating the
contribution each pairwise estimate makes to each
network meta‐analytic estimate in the absence of covari-
ates.19-21 Caldwell et al also used similar methodology to
calculate the precision of a network meta‐analysis
treatment effect.13 We extend the method to compute
the contribution each trial makes to each NMR treatment
effect estimate and to each regression coefficient estimate
for a treatment by covariate interaction.
Recently, methods were proposed for calculating
study weights in multi‐parameter meta‐analysis.22,23
Neither article presented methods specifically for NMR
or discussed contributions of covariate values, extrapola-
tion, or interpolation. Yet, such methods can be applied
to NMR without modification. We compare the new
methods proposed here in with those presented by
Riley et al.23
The methods introduced in this paper are applicable
for both continuous and categorical covariates and trial‐
level aggregate outcome data. In Section 2, we introduce
2 datasets that are used to illustrate the methods. We out-
line existing NMR models in Section 3. In Section 4, we
introduce new methods for calculating the contribution
that each trial makes to each NMR result and compare
them with those presented by Riley et al.23 New methods
are described for fixed‐effect and random‐effects models,
Bayesian, and Frequentist frameworks, and models
that make different assumptions regarding the regression
coefficients for the treatment by covariate interactions. In
Section 5, we propose novel graphs that will help
interpret NMR results with the covariate distribution
and contributions in mind. In Section 6, we discuss the
proposed methods and findings.2 | ILLUSTRATIVE DATASETS
The proposedmethods will be demonstrated using 2 exam-
ple aggregate datasets; a dataset of 3 treatments for severe
malaria with a dichotomous outcome where the treatment
effects are measured on the log odds ratio scale and
another dataset of topical fluoride interventions for
preventing dental caries, which is a much larger network,
involving a continuous outcome with treatment effects
measured by the standardised mean difference (SMD).
The malaria dataset was constructed using 2 Cochrane
reviews and trial reports; 1 review compared artesunate
(AS) versus quinine (QU) and the second compared
artemether (AR) versus QU and AS versus AR.24,25 Both
reviews included randomised controlled trials includingpatients with severe malaria. Results were stratified by
age in the reviews, and therefore age was considered to
be a treatment effect modifier. Event rates for the primary
outcome, death, were extracted from the reviews and data
were cross‐checked against the trial reports. The covari-
ate, average age of patients, in each trial was extracted
from the trial reports. Two studies with missing covariate
data were deleted from the dataset. Log odds ratios and
their standard errors were calculated for each trial in R
using the event rates. Table S1 displays the data.
The fluoride dataset was originally constructed using
several Cochrane reviews and has been used previously
to demonstrate network meta‐analysis methods in the
methodological literature.17,26-33 Reviews included
randomised or quasi‐randomised controlled trials that
used or indicated blind outcome assessment and com-
pared different forms of topical fluoride interventions for
preventing dental caries in children or adolescents with
a duration of at least 1 year or school year. Six treatments
were compared, that is, no treatment (NT), placebo (PL),
fluoride in dentifrice (DE), fluoride in rinse (RI), fluoride
in gel (GE), and fluoride in varnish (VA). The primary
outcome was caries increment in permanent teeth mea-
sured by the change from baseline in decayed, missing,
and filled tooth surfaces. For each trial, for each treatment
group, the number of participants, mean caries incre-
ment, and the corresponding standard deviation were
obtained. The covariate, randomisation year, of each trial
was also obtained. Specifically, the year of randomisation
was taken to be the same as the year the study began but
for trials where the year a study began was not accessible
it was estimated by subtracting the duration of the trial (in
years) plus 1 extra year from the publication year. Previ-
ously, Salanti et al found an interaction between treat-
ment effect and randomisation year and we explore this
interaction further.17 As in the previous article, SMDs
were used to compare treatments. SMDs, their standard
errors and covariances (for multi‐arm trials) were
calculated for each trial in R using formulae specified by
Cooper et al.34 See Table S2 for the data.3 | NETWORK META ‐REGRESSION
MODELS
3.1 | Model specification
Let i denote the trial where i = 1, ……, N and N is the num-
ber of independent trials and let k be the trial arm where
k = 1, ……, Ai and Ai is the number of arms in trial i. Let tik
denote the treatment given in trial i in arm kwhere tik∈ {1,
……,T} and T is the number of treatments in the network.
Note that treatment 1 is taken to be the reference
treatment.
4 DONEGAN ET AL.Suppose we have trial‐level outcome data, where yik is
the observed treatment effect (eg, log odds ratio) for arm k
vs arm 1 (with k ≥ 2) in trial i and vik is the corresponding
variance. We assume a normal likelihood yik~N(θik,vik)
where θik is the mean treatment effect in trial i (with
k ≥ 2). Let ci be a study‐level covariate for trial i (such
as, a continuous covariate value or an indicator variable
for a dichotomous covariate).
There are 3 different assumptions that can be made
regarding the basic regression coefficients for the treat-
ment by covariate interactions, that is, they are indepen-
dent, exchangeable, or common.6,14,15,35 The basic
regression coefficients are the coefficients for each treat-
ment versus the reference treatment 1 (ie, β12, β13, …,
β1T, where, for example, β12 is the regression coefficient
for treatment 2 versus treatment 1). The decision regard-
ing which assumption is most appropriate for a specific
dataset can be based on the model fit, data availability,
the resulting estimates of the regression coefficients, and
clinical judgement.
The NMRmodel with independent interactions can be
written as
θik ¼ δik þ βti1;tik ci
where βti1;tik=β1;tik ‐β1;ti1 , βti1;tik is the difference in the
treatment effect of tik vs ti1 per unit increase in the covariate
ci, or in other words, the regression coefficient for the treat-
ment by covariate interaction for tik vs ti1. In a random‐
effects model, δik (with k ≥ 2) represents the trial‐specific
treatment effect treatment effect in trial i for arm k vs
arm 1 when the covariate is zero (or when the covariate
is the mean value if the model is centred at the mean)
and is assumed to be a realisation from a normal distribu-
tion where δik∼Ν dti1;tik ; σ2
 
with dti1;tik ¼ d1;tik−d1;ti1 and
dti1;tik is the mean treatment effect of tik vs ti1 when the
covariate is zero (or when the covariate is the mean value
for centred models). Here, the between trial variance σ2 is
assumed to be the same for each comparison; this assump-
tion is often made in the network meta‐analysis literature
and applications to aid estimation.
In a fixed‐effect model, we set σ2 = 0 to obtain δik=
d1;tik−d1;ti1 . The NMRmodel with exchangeable interactions
is given by letting β1;tikeNorm B; υ2ð Þ and the model with
common interactions is formulated by settingβ1;tik ¼ β. With
common interactions, the functional regression coefficients
(ie, βti1;tik where ti1 ≠ 1) are fixed to be zero.
35
When multi‐arm trials contribute, the correlation
between the observed treatment effects (yik) and the
trial‐specific treatment effects (δik) from the same study
must be taken into account in the modelling; details are
described in the supplementary material.3.2 | Application to datasets
NMR models were fitted using WinBUGS 1.4.3 and the
R2WinBUGS package in R. Fixed‐effect and random‐
effects models including independent, exchangeable, and
common interactions were applied. The correlation
between treatment effects from the same trial was taken
into account in the models when multi‐arm trials existed.
The covariates were centred at their mean. All parameters
were given non‐informative normal prior distributions
(ie, N(0, 100000)) except the between trial standard devia-
tion that was assumed to follow a non‐informative
uniform distribution (ie, Uni(0, 10)). Three chains with
different initial values were run for 300 000 iterations.
The initial 100 000 draws were discarded, and chains were
thinned such that every fifth iteration was retained. See
supplementary code S1.
Model fit and complexity of fixed‐effect and random‐
effects models was assessed using the deviance informa-
tion criterion (DIC) defined as DIC ¼ Dþ pD where
pD ¼ D−bD and D was the posterior mean residual devi-
ance, pD was the effective number of parameters, and bD
was the deviance evaluated at the posterior mean of the
model parameters.36 A model with a comparatively
smaller DIC was preferable to a model with a larger
DIC; when the difference in DIC was very small, the
difference was not considered meaningful; and in this
case, the simpler fixed‐effect models were preferred to
random‐effects models and the model with independent
interactions was preferred because it makes the weakest
assumption regarding the coefficients.3.2.1 | Malaria dataset
The results from the fixed‐effect NMR with independent
interactions are shown in Table S3. Results from this
model are presented because the DICs from each applied
model were similar (DICs 22.95–26.13). There is evidence
of an interaction between log odds ratio and average age
for AS vs QU. As the average age ranged from 2.33 to
34.47 years across trials, log odds ratios at mean age, 0,
5, 10, 15, 20, 25, 30, and 35 years are displayed. For AS
vs AR, none of the displayed log odds ratios indicate a
difference between the drugs. However, each of the log
odds ratios suggests a difference between AS and QU,
and a difference between AR and QU is observed for log
odds ratios estimated for age 15 years or more. The results
of the NMR could be used to draw clinical inferences
because an interaction has been found. However, to aid
interpretation, we must first consider which trials and
covariate values contribute to each result to be aware of
extrapolation and interpolation.
DONEGAN ET AL. 53.2.2 | Fluoride dataset
Table S4 displays the results from the random‐effects
NMR model including independent interactions. This
model provided a lower DIC (DIC = 546.67) than the
fixed‐effects models with independent (DIC = 797.41),
exchangeable (DIC = 798.82), and common interactions
(DIC = 809.14); results from the random‐effects models
were similar (DIC = 546.67–547.04). The posterior
median of the between trial variance is 0.03 with 95%
credibility interval (0.02, 0.05). The results show that
there is an interaction between the SMD and
randomisation year for VA vs PL. SMDs at year 1954,
1960, 1970, 1980, 1990, and 1994 are presented because
the randomisation year across all the trials ranged from
1954 to 1994. For DE, RI, GE, vs NT and DE vs PL, there
is a difference between the 2 interventions being com-
pared for each displayed SMD. For VA vs NT and RI vs
PL, a difference is found for SMDs estimated for years
1954, 1960, 1970, 1980, and 1990. Whereas, for PL vs
NT, a difference is found between 1970 and 1990, and
for GE and VA vs PL, a difference is observed between
1954 and 1980. Salanti et al concluded that “older studies
gave more enthusiastic results for the effectiveness of
fluoride” and the NMR results in our article agree with
this conclusion.17 However, to further explore the results,
we need to consider which trials and covariate values
contribute to each result.4 | CALCULATING THE TRIALS '
CONTRIBUTIONS
4.1 | Methods
In the supplementarymaterial, details are provided regard-
ing the newmethods for calculating the percentage contri-
bution that each trial makes to each NMR result (ie, each
dti1;tik and each βti1;tik ). For each NMR result, the amount
that each trial contributes to the result is estimated; the
contributions across all trials sum to 100%. The methods
can be used assuming either fixed or random treatment
effects, and assuming independent, exchangeable, or com-
mon interactions. Methods are described for a Frequentist
approach and Bayesian framework including prior infor-
mation. In a Bayesian framework, the contribution that
the prior distributions make to each NMR result can also
be calculated, whichmay be useful when informative prior
distributions are used. The methods can be applied to
datasets that include multi‐arm trials because they can
allow for the correlation between treatment effects from
the same trial.
A summary of the existing methods proposed by Riley
et al to calculate trial contributions is also given in thesupplementarymaterial.23 The existingmethods have been
applied in a Frequentist framework, can assume either
fixed or random treatment effects, and accommodate
multi‐arm trials. However, at present, the existingmethods
do not allow for the inclusion of prior information in a
Bayesian setting. The current methods can calculate the
contribution that each trial makes to each basic treatment
effect (ie, dti1;tik where ti1 = 1) and to each basic regression
coefficient (ie, βti1;tik where ti1 = 1). Providing the model's
results does not depend on the choice of reference treat-
ment, the contribution that each trial makes to each func-
tional treatment effect (ie, dti1;tik where ti1 ≠ 1), and each
functional coefficient (ie, βti1;tik where ti1 ≠ 1) can be calcu-
lated by re‐applying the methods with different treatments
coded as the reference treatment. Therefore, the existing
methods cannot be used assuming exchangeable or com-
mon interactions because the results of such models can
differ depending on the choice of reference treatment.4.2 | Application to datasets
We used R and Excel to calculate the studies' contribu-
tions using the new methods. The methods by Riley et al
were applied using Stata and verified using R.23 The
covariates were centred at their mean. Computing code
is supplied (code S2).4.2.1 | Malaria dataset
Using the new methods, the contribution of each trial to
each log odds ratio and each regression coefficient is
shown in Table S5. Study contributions vary between 0
and 49.86%. Notice that each contribution column sums
to 100%. Generally, a trial will contribute different
amounts to each NMR result, for example, van Hensbroek
1996 contributes 25.70% to the log odds ratio of AR vs QU
and 14.00% to the coefficient for AS vs AR. Also, different
trials contribute different amounts to each NMR result,
for example, for the coefficient for AS vs QU, Dondorp
2010 contributes 46.26% whereas Adam 2002 contributes
0.00%. It is clear that the contribution a study makes to
a log odds ratio is generally similar but not identical to
the contribution it makes to the corresponding regression
coefficient, for example, van Hensbroek 1996 contributes
25.70% to the log odds ratio of AR vs QU and 21.00% to
the coefficient for AR vs QU.
Table S6 displays the study weights for each NMR result
calculated using the existing methods proposed by Riley
et al.23 Contributions were similar but not identical to those
calculated using the newmethods with absolute differences
between results varying from 0 to 15.29%. The NMR results
obtained from Stata were the same as those in Table S3.
6 DONEGAN ET AL.4.2.2 | Fluoride dataset
The contribution of each trial to each SMD and each regres-
sion coefficient is displayed in Table S7 using the new
methods. Study contributions vary between 0% and 12.7%;
therefore, no single study dominates a particular NMR
result. Analogous to the malaria dataset, a trial will contrib-
ute different amounts to each NMR result, different trials
contribute different amounts to each NMR result, and the
contribution a study makes to a log odds ratio differs from
the contribution it makes to the corresponding coefficient.
Note that when the NMR model was refitted in Stata to
calculate the study weights using the existing Frequentist
methods proposed by Riley et al, the NMR results differed
marginally (see Table S8).23 Table S9 displays the study
weights for each NMR result calculated from the existing
method. The contributions from the existing method were
not exactly the same as those from the new method. The
absolute differences between results varied from 0 to 18.64%.5 | GRAPHICAL DISPLAYS
The proposed graphs aid interpretation of NMR results by
displaying the covariate distributions or study contribu-
tions. Graphs include a network covariate distribution
diagram, covariate‐contribution plot, heat plot, contribu-
tion‐NMR plot, and heat‐NMR plot.
Covariate‐contribution plots, heat plots, contribution‐
NMR plots, and heat‐NMR plots were constructed in R.
Example code is provided in the supplementary material
(code S3‐S6). We chose to use the contributions calculated
from the new methods in the graphs but equally, the
contributions estimated by the methods of Riley et al
could be used.235.1 | The network covariate distribution
diagram
5.1.1 | Graph description
A standard network diagram displays nodes and edges; the
nodes represent the treatments and each edge (ie, a
connecting line), which join 2 nodes, represents the avail-
ability of outcome data from studies that directly compare
the 2 treatments. Such diagrams are widely used to visually
display the available evidence and can be constructed using
various software and display options.19,37 The proposed net-
work covariate distribution diagram is an adaptation of the
standard network diagram in that the covariate values of
trials are also displayed on the diagram. For each edge (ie,
treatment comparison with direct evidence), a histogram
of the covariate values can be drawn with the edge consid-
ered analogous to the horizontal axis of the histogram.Furthermore, for large networks, the diagrams can
become cluttered; therefore, instead, histograms of the
covariate values can be drawn alongside the network
diagram. Alternatively, a 3‐dimensional version of the
diagram can be drawn, with the treatment network drawn
on a 2‐dimensional plane and the covariate distributions
plotted in a third dimension; Batson et al propose a simi-
lar diagram and have produced a computer package to
draw such graphs.38
The purpose of the network covariate distribution
diagram is to visualise the covariate values in addition to
the evidence base. For each comparison, it is useful to
understand the range of covariate values contributing
direct evidence because NMR parameter estimation issues
may be identified, for example, it would not be possible to
fit a model with independent interactions when only 1
trial contributes to a basic regression coefficient or when
all the studies that contribute to a basic coefficient have
the same covariate value. Also, interpolation and extrapo-
lation may be detected from the diagram when no trials
with covariate values within a particular covariate range
exist. However, it is difficult to draw conclusions regard-
ing the overall covariate range relevant for each compari-
son from this diagram because indirect evidence also
contributes to the NMR results.5.1.2 | Application to datasets5.2 | Malaria dataset
Figure 1 shows the network covariate distribution dia-
gram. As this dataset is a 3 treatment network, histo-
grams can be drawn into the diagram. It is apparent
that the distribution of the average ages of the patients
in trials that contribute direct evidence differs across
comparisons. There are no paediatric trials directly com-
paring AS vs AR. However, this may not be a concern
because the network is a 3 treatment loop; therefore,
all the trials in the network and their covariate values
should contribute to all NMR results, but it is not obvi-
ous by how much each trial contributes to each NMR
result. Furthermore, we see that no trials have an aver-
age age between approximately 10 and 20 years, so
results are interpolated within this range; however, if
some trials contribute very little to some results, the
range for interpolation may be wider than this for some
comparisons.5.3 | Fluoride dataset
As the fluoride dataset is a larger network, a network
diagram including covariate data is cluttered (diagram
FIGURE 1 Network covariate distribution diagram for the malaria dataset
DONEGAN ET AL. 7not presented), and therefore it is preferable to present
covariate information separately to the diagram.
Figure 2 shows the network diagram, and Figure 3FIGURE 2 Network diagram for the fluoride dataset.DE:
dentifrice; GE: gel; NT: no treatment; PL: placebo; RI: rinse; VA:
varnish. Numbers of studies contributing direct evidence are displayedpresents covariate information. There are certainly dif-
ferences in the distribution of randomisation year across
comparisons with many comparisons having a very narrow
range of years (Figure 3). However, the network is fully con-
nected (ie, every intervention is directly compared with
every other intervention); therefore, one would expect all
trials to make some contribution to each NMR result.5.4 | The covariate‐contribution plot
5.4.1 | Graph description
A covariate‐contribution plot consists of 1 graph per NMR
result, that is 1 graph for each treatment effect at zero covar-
iate and each regression coefficient. For each NMR result,
the percentage contribution that each trial makes to the
NMR result is plotted on the vertical axis against the covar-
iate value for each study on the horizontal axis; 1 point per
study is displayed on the graph. Various display options can
be considered in the plot. The study number can be
displayed in the graph rather than a standard plotting point
FIGURE 3 Distributions of randomisation year for the fluoride dataset.DE: dentifrice; GE: gel; NT: no treatment; PL: placebo; RI: rinse;
VA: varnish
8 DONEGAN ET AL.symbol so that the contribution a particular study makes to
different NMR results can be compared.
Moreover, for large networks, where the number of
NMR results is large, 1 graph per comparison can be con-
structed, rather than 1 graph per NMR result, with the
contributions to the treatment effect and the contribu-
tions to the coefficient displayed on a single graph but
using different colours or plotting symbols.
The aim of the plot is to show which trials and covar-
iate values contribute to each result. A key advantage of
the plot is that if extrapolation or interpolation exists, it
is clearly visible from this plot. Furthermore, it can be
useful to know which studies and covariate values con-
tribute to which results when considering causes of any
existing inconsistency.5.4.2 | Application to datasets5.5 | Malaria dataset
The contribution of each trial to each log odds ratio and
each regression coefficient is shown in the covariate‐contri-
bution plot in Figure 4. For this dataset, we present separate
plots showing the contributions to the log odds ratios
(Figure 4A,C,E) and regression coefficients (Figure 4B,D,
F), and we display the study numbers instead of points.
Figure 4 shows that no trials have an average age between
7 and 25 years, and therefore results are interpolated withinthis range for each NMR result. For each comparison, spe-
cific studies do seem to dominate the NMR result. For
example, for AS vs QU, studies 18 and 19 contribute
32.22% and 49.86%, respectively, to the log odds ratio and
33.52% and 46.26% to the coefficient; the average ages of
patients in these studies are 27.90 and 2.85 years. Therefore,
we may bemore confident in drawing conclusions for these
average ages. Whereas, studies with average ages of 3 to
7 years, 25 to 27 years, and over 28 years contribute little
for AS vs QU; therefore, we may be less confident about
interpreting the result within this range (Figure 4C,D).5.6 | Fluoride dataset
Figure 5 is the covariate‐contribution plot showing the
contribution of each trial to each SMD and each regres-
sion coefficient. As many treatments are compared in this
dataset, we chose to present 1 graph per comparison and
red points to represent the contributions to the SMDs
and blue points to represent the contributions to the
regression coefficients. The figure clearly shows that, for
each comparison, a wide range of covariate values con-
tribute to the NMR results with no obvious areas of inter-
polation or extrapolation. For most comparisons, the
percentage contributions are relatively similar across
covariate values such that the contributions do not
decrease or increase with increasing randomisation year.
Also, no single study dominates a particular comparison,
that is, all contributions are less than 15%.
FIGURE 4 Covariate‐contribution plot showing average age versus percentage contribution of each trial to each log odds ratio and each
regression coefficient for the malaria dataset.Numbers represents the study number in Table S1
DONEGAN ET AL. 95.7 | Heat plot
5.7.1 | Graph description
For continuous covariates, to construct the heat plot, first,
suitable ranges of the covariate are chosen (eg, trial dura-
tion 12–24 weeks, 24–36 weeks,,,….). Then, for each NMR
result, the contributions can be summed across trials
within the same covariate range to give the contribution
of the covariate range to the result. For instance, for a par-
ticular NMR result, the contributions of trials that have a
covariate value between 12 and 24 weeks would be
summed and similarly, summed for trials with values
between 24 and 36 weeks; from this, we may find that the
result is 80% from trials with values 12 to 24 weeks and
20% from trials with values 24 to 36 weeks. For categorical
covariates, a similar approach is taken by summing the
contributions of trials within each covariate category.
The summed contributions are then displayed on the
heat plot. The heat plot displays how much each covariate
range contributes to each NMR result using a matrix for-
mat. Each cell of the matrix shows the contribution of a
covariate range to an NMR result by displaying thenumerical contributionandusing colour shading (eg, lower
contributions represented using blue shades and higher
contributions represented using red shades). The heat plot
is particularly useful for highlighting covariate ranges
where an NMR result is extrapolated or interpolated.5.7.2 | Application to datasets5.8 | Malaria dataset
Figure 6 shows the heat plot. Trialswere grouped according
to the average age of patients using intervals of 2.5 years,
ranging from zero to 35 years. For AS vs AR and AR vs
QU, the contributing trials have average ages within range
0 to 7.5 years and 22.5 to 32.5 years; therefore, results would
be interpolated or extrapolated outside of these ranges.
Similarly, for AS vs QU, trials within range 2.5 to 7.5 years
and 22.5 to 35 years contribute to results. The plot shows
that results between 7.5 and 22.5 years are interpolated
for all comparisons. Within each age group, the contribu-
tions vary across NMR results, for instance, trials with
FIGURE 5 Covariate‐contribution plot showing randomisation year versus percentage contribution of each trial to each SMD and each
regression coefficient for the fluoride dataset.DE: dentifrice; GE: gel; NT: no treatment; PL: placebo; RI: rinse; VA: varnish [Colour figure
can be viewed at wileyonlinelibrary.com]
FIGURE 6 Heat plot showing average
age versus the NMR result for the malaria
dataset.Block colour and numbers
represent the contribution of each
covariate range to each log odds ratio and
each regression coefficient (%).AR:
artemether; AS: artesunate; QU: quinine
[Colour figure can be viewed at
wileyonlinelibrary.com]
10 DONEGAN ET AL.average age between 2.5 and 5 years contribute 36% to the
regression coefficient for AR vs QU but contribute 51% to
the regression coefficient for AS vs AR.5.9 | Fluoride dataset
The heat plot is shown in Figure 7. Trials were grouped
with respect to randomisation year using intervals of5 years. For most NMR results, the majority of the con-
tributing trials have randomisation years between 1960
and 1979. There are no contributing trials randomised
between 1954 and 1959 for most NMR results, and there
are no contributing trials randomised between 1985 and
1989 for 1 NMR result; therefore, these results would be
extrapolated if interpreted within these ranges. The
observed contributions vary across NMR results within
FIGURE 7 Heat plot showing randomisation year versus the NMR result for the fluoride dataset. Block colour and numbers represent the
contribution of each covariate range to each SMD and each regression coefficient (%)DE: dentifrice; GE: gel; NT: no treatment; PL: placebo;
RI: rinse; VA: varnish. [Colour figure can be viewed at wileyonlinelibrary.com]
DONEGAN ET AL. 11each randomisation year range, as well as varying across
randomisation year ranges for each NMR result.5.10 | The contribution‐NMR plot
5.10.1 | Graph description
The aim of the contribution‐NMR plot is to display the
results of the NMR as well as the study data points in a
similar way to a bubble plot that is often used to display
standard pair‐wise meta‐regression. This enables the
NMR results to be interpreted while also considering the
covariate distributions.
The contribution‐NMR plot consists of 1 graph per
treatment comparison. Each graph has 2 sections.
The bottom section of the graph is a plot of the treat-
ment effect on the vertical axis versus the covariate value
on the horizontal axis. The NMR regression line (and its
95% confidence or credibility interval) for that compari-
son is drawn to show the NMR treatment effects
estimated at various covariate values. Points plotted for
each study that contributes direct evidence at the
observed trial's treatment effect and covariate value.
The top section of the graph displays a plot of covari-
ate value on the horizontal axis. Points are plotted for
each study contributing indirect evidence to that compar-
ison at the observed covariate value. Notice that there are
no observed treatment effects for trials contributing
indirect evidence; therefore, the points could not plotted
in the bottom section but can be plotted in the top section
because there is no treatment effect scale on the
vertical axis.To display the contributions on the plot, the size of the
contribution that a study makes to a NMR result can be
represented by the size of a point for that study. For a par-
ticular comparison, the size of the contribution that a
study makes to the treatment effect at zero covariate
may differ from the contribution it makes to the corre-
sponding regression coefficient; therefore, 2 points of dif-
ferent sizes must be plotted in the same place because
they represent the same study. We recommend using a
circle as the plotting symbol so that the 2 points for each
study can both be seen simultaneously even when they
are over‐layered on the plot; a red circle whose size repre-
sents the contribution of a study to the treatment effect
and a blue circle whose size represents the contribution
of the same study to the regression coefficient. When the
circles are large and do not fit inside the plotting region,
the contribution values can be rescaled by dividing all
contributions by an appropriate scalar value so that circles
fit in the region and are visually pleasingly.
However, it is worth noting that to simplify the plot,
information regarding contributions can be ignored such
that 1 point per study is plotted where all plotting points
have the same standard size.
The contribution‐NMR plot shows which trials and
covariate values contribute most to each NMR result,
whether results are evidence based or have been interpo-
lated or extrapolated and whether treatment by covariate
interactions exist. Furthermore, differences between the
covariate distribution of trials contributing direct evi-
dence and the covariate distribution of trials contributing
indirect evidence for a particular comparison are obvious
from the plot, and as such, the plot facilitates exploration
of causes of inconsistency.
12 DONEGAN ET AL.5.10.2 | Application to datasets5.11 | Malaria dataset
Figure 8 displays the contribution‐NMR plot. Contribu-
tions were scaled by a fifth. Results are interpolated
between around average age 7 to 25 years. For AR vs QU,
results are mostly based on 2 direct evidence trials and 2
indirect evidence trials approximately within ranges 0 to
5 years and 28 to 35 years. For AS vs QU, 2 direct evidence
trials mostly contribute to the results around range 0 to
5 years and 25 to 30 years. Results for AS vs AR are mostly
based on indirect evidence trials approximately within
range 0 to 7 years and 28 to 35 years. Figure S1 shows the
same plot but without presenting the study contributions.
5.12 | Fluoride dataset
The contribution‐NMR plot is shown in Figure 9. Contri-
butions were scaled by a half. For all comparisons exceptFIGURE 8 Contribution‐NMR plot for the malaria dataset. The bold d
and lower 95% credibility intervals estimated by the model. Points (ie, circ
for trials that contribute direct evidence are displayed in the bottom sec
displayed in the top section. The size of the red circle represents the size
at mean value), and the size of the blue circle represents the size of the
circles represent larger contributions [Colour figure can be viewed at wi7 (ie, PL vs NT, DE vs NT, DE vs PL, RI vs PL, RI vs DE,
GE vs DE, and VA vs DE), there are no contributing trials
randomised before 1960; therefore, results are extrapo-
lated for low randomisation years. The plot clearly shows
that for many comparisons (ie, PL vs NT, DE vs NT, RI vs
DE, GE vs DE, VA vs DE, GE vs RI, VA vs GE), NMR
results are based on no or very limited direct evidence.
A simpler version on the plot that does not display the
study contributions is shown in Figure S2.5.13 | Heat‐NMR plot
5.13.1 | Graph description
The contribution‐NMR plot was devised to simulta-
neously display the results of the NMR and the contribu-
tions of various covariate ranges to the NMR results so
that the NMR results can be interpreted with the covariate
distribution in mind.ot‐dash line is the log odds ratio, and the 2 dashed lines are the upper
les) represent the trials that contribute to the model estimates; points
tion, and points from trials that contribute indirect evidence are
of the contribution that a trial makes to the log odds ratio (estimated
contribution that a trial makes to the regression coefficient. Larger
leyonlinelibrary.com]
FIGURE 9 Contribution‐NMR plot for the fluoride dataset. The bold dot‐dash line is the SMD, and the 2 dashed lines are the upper and
lower 95% credibility intervals estimated by the model. Points (ie, circles) represent the trials that contribute to the model estimates; points
for trials that contribute direct evidence are displayed in the bottom section, and points from trials that contribute indirect evidence are
displayed in the top section. The size of the red circle represents the size of the contribution that a trial makes to the SMD (estimated at mean
value), and the size of the blue circle represents the size of the contribution that a trial makes to the regression coefficient. Larger circles
represent larger contributions. DE: dentifrice; GE: gel; NT: no treatment; PL: placebo; RI: rinse; SMD: standardised mean difference; VA:
varnish [Colour figure can be viewed at wileyonlinelibrary.com]
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parison. Like the contribution‐NMR plot, for each treat-
ment comparison, a graph of treatment effect on the
vertical axis versus covariate value on the horizontal axis
is constructed with the NMR regression line and its 95%
confidence or credibility interval displayed.
However, in the heat‐NMR plot, the area between the
upper and lower confidence or credibility bounds is
coloured. The summed contributions calculated for the
heat plot are used to colour the area so that the covariate
ranges with higher contributions are coloured red shades
and the ranges with lower contributions are coloured blue
shades. As the contribution to the treatment effect may
differ from the contribution to the regression coefficient,
2 colours must be displayed for the same covariate range;
consequently, the area between the upper interval and the
NMR regression line displays the colour shades for thetreatment effect, and the area between the lower interval
and the NMR regression line displays the colour shades
for the coefficient.
The heat‐NMR plot display whether treatment by
covariate interactions exist, areas of interpolation or
extrapolation, and which covariate ranges contribute
most to each NMR estimate.5.13.2 | Application to datasets5.14 | Malaria dataset
The heat‐NMR plot is shown in Figure 10. For each com-
parison, most of the contributing trials are within range
2.5 to 5 years and 25 to 32.5 years so we can be most
FIGURE 10 Heat‐NMR plot showing average age versus log odds ratio for the malaria dataset. The bold dot‐dash line is the log odds ratio,
and the 2 dashed lines are the upper and lower 95% confidence intervals estimated by the model. Block colours represent the contribution of
each covariate range to each log odds ratio and each regression coefficient (%) [Colour figure can be viewed at wileyonlinelibrary.com]
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within these average age ranges.5.15 | Fluoride dataset
Figure 11 shows the heat NMR‐plot. For the majority of
comparisons, we can be most confident in the NMR
results between 1960 to 1980 because most of the contrib-
uting trials were randomised within this time period.6 | DISCUSSION
The proposed methods can help one to understand which
trials and covariate values contribute to each NMR result
and highlight extrapolation or interpolation. For both
example datasets, we found that the contribution that
each trial made to each NMR result varied. For the
malaria dataset, for every NMR result, no contributing tri-
als had an average age between 7 and 25 years; thus,
results were interpolated. For the fluoride dataset, there
were no contributing trials randomised between 1954
and 1959 for most NMR results and no contributing trials
randomised between 1985 and 1989 for some NMR
results; therefore, within these ranges, these results would
be extrapolated. However, we anticipate that in otherdatasets, the extrapolated or interpolated range may differ
more strongly across comparisons, for example, extrapola-
tion within covariate range 7 to 25 years for treatment 3 vs
treatment 2 but extrapolation within covariate range 25 to
40 years for treatment 3 vs treatment 1.
It may be argued that if one truly believes that the
model is appropriate and its underlying assumptions are
valid, then extrapolated and interpolated results should
be of no concern. Yet, we believe that such occasions are
likely to be rare because often in an aggregate data NMR,
it is difficult to detect whether the consistency assumptions
are feasible because of data limitations. Furthermore, if
inconsistency is present for a particular treatment compar-
ison in the NMR, it is likely to be caused by differences
in the distribution of a covariate from trials that contribute
direct evidence and those that contribute indirect
evidence. The proposed methods, in particular the contri-
bution‐NMR plot, can help to visualise such differences
and therefore understand causes of the inconsistency.
In this article, we have provided newmethods to calcu-
late contributions based on models with independent,
exchangeable, or common interactions. We applied
models including independent interactions, but in some
scenarios, this model cannot be fitted, and modellers may
apply models with exchangeable or common interactions
instead. For instance, when all the trials that contribute
FIGURE 11 Heat‐NMR plot showing randomisation year versus SMD for the fluoride dataset.The bold dot‐dash line is the SMD, and the 2
dashed lines are the upper and lower 95% confidence intervals estimated by the model. Block colours represent the contribution of each
covariate range to each SMD and each regression coefficient (%)DE: dentifrice; GE: gel; NT: no treatment; PL: placebo; RI: rinse; SMD:
standardised mean difference; VA: varnish. [Colour figure can be viewed at wileyonlinelibrary.com]
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covariate value, which can be problem especially when cat-
egorical covariates are considered. In these cases, the
exchangeable or common model could be fitted providing
that studies that contribute to the results for other compar-
isons have different categories. For example, when explor-
ing an interaction between treatment effect and study
location (ie, continent), studies that contribute to results
for comparison 2 vs 1 may all be carried out on the same
continent provided that studies that contribute to compar-
ison 3 vs 1were located on different continents. Thismeans
that NMR results can be obtained for a comparison even
though there is no direct or indirect evidence for the regres-
sion coefficient for that comparison, and hence results on
that comparison are not evidence based.
If data are limited, an alternative to using models with
exchangeable or common interactions would be to use
informative prior distributions in a Bayesian framework.
Methods have been presented in this article that can be
used with such prior distributions allowing the contribu-
tion that the prior distribution makes to each NMR result
to be calculated as well as the study contributions. In
these situations, informative prior distributions would
ideally be evidence based, perhaps elicited from other
similar meta‐analyses or expert opinion.
As with all meta‐regression methods, there may be
missing covariate data or covariate data may be reported
using different statistical summarises across trialsmeaning that it is not possible to combine all trials. In
such situations, ideally the data should be sought from
the original trial investigators. If contact with investiga-
tors is not fruitful, it may be possible to impute covariate
data, the relevant studies could be deleted from the
dataset, and/or sensitivity analyses could be carried out
to explore the impact of the missing or imputed data on
the results.
In this article, we introduced methods to calculate the
contribution that each study makes to each NMR result
and compare the methods with the existing methods
described in Riley et al for calculating study weights in
multi‐parameter meta‐analysis than can also be applied
to NMR.23 When both methods were applied to real data,
we found differences in the estimated contributions. Dif-
ferences may exist for the fluoride dataset, because, when
multi‐arm trials exist, the methods proposed by Riley et al
estimate the contribution that the study makes to each
NMR result, whereas the new methods estimate the con-
tribution that each data point (ie, each observed treatment
effect for that study) makes to each NMR result.23 Fur-
thermore, the results of the NMR estimated using the
Frequentist methods of Riley et al differed from those
obtained using Bayesian methods.23 Also, it is worth
emphasising that the previously proposed methods on
which our methods are based have been criticised
because the estimated contributions are not invariant
to transformations of the data, such that if the data
16 DONEGAN ET AL.are rescaled, the contributions matrix changes19-21;
whereas the methods proposed by Riley et al produce
the same contributions even when the data are trans-
formed.22,23 Further work may adapt the methods of
Riley et al to accommodate NMR models with
exchangeable or common interactions and perhaps prior
information in a Bayesian setting, so that the methods
can be applied in all situations.23
As an alternative method to calculating study contri-
butions, we could have used more similar methods to
those proposed elsewhere by fitting a standard pairwise
meta‐regression to each comparison in the treatment net-
work to estimate a treatment effect and regression coeffi-
cient for each comparison, and then calculating the
contribution that each of the pair‐wise treatment effects
and coefficients makes to each NMR result.19-21 There-
fore, unlike the methods proposed in this article, the alter-
native method would not provide the contribution of each
trial to each NMR result. The alternative approach could
not be used when only 1 trial contributed direct evidence
to 1 or more comparisons because a regression coefficient
could not be estimated for that comparison, whereas the
methods proposed in this article may be used. Also, the
conclusions drawn regarding extrapolation and interpola-
tion would be less intuitive; for example, the alternative
method would allow one to state that a particular NMR
result was based on pairwise estimates that were esti-
mated using trials within range X‐Y; yet, the proposed
methods can tell one how much each covariate value con-
tributed to an NMR result.
In this paper, we calculated contributions by model-
ling trial‐level aggregate data (ie, treatment effects and
variances). Individual patient data models can be advan-
tageous over aggregate data models when studying
patient‐level covariates because they avoid ecological
biases.39,40 Yet, it is common to explore patient‐level
covariates (eg, patient age) using study‐level covariate
summaries (eg, average age of patients) in meta‐regres-
sion such as in the malaria dataset. In these instances,
the treatment effect is estimated from all patients with
potentially widely variable covariate values, yet the full
covariate distribution for each study is ignored in the
meta‐regression. The methods presented in this article
do not show how the “ignored” covariate values contrib-
ute to the NMR results. Therefore, the methods presented
in this article are limited when patient‐level covariates are
of interest, in the same way that existing meta‐regression
methods are also limited in such circumstances. Exten-
sion of the new methods to individual patient data and
other types of aggregate data, such as event rates, and
are not straightforward because iteratively weighted least
squares estimation with transformed observations is
required.Standard pairwise meta‐regression is a special case of
NMR, and so the methods presented here can also be
applied to aid analysts' interpretation of pair‐wise meta‐
regression by providing a better understanding of the
covariate distribution of trials. In principle the proposed
methods can be applied for any number of treatments
without adaptation; but of course, the number of plots
increases with the number of treatments. The methods
also apply when multiple covariates are included in the
NMR simultaneously. With multiple covariates, the
network covariate distribution diagram would display
multiple histograms on each edge; therefore, a 3D figure
may be favourable (or the histograms can be presented
in 2D separate to the network diagram); the covariate‐
contribution plot would include graphs showing, for each
comparison, the contributions to the treatment effect and
the contributions to each regression coefficient; 1 heat
plot for each covariate would be constructed; and the con-
tribution‐NMR plot and heat‐NMR plot would include 1
graph for each covariate for each comparison. The
methods in this article can also be applied to categorical
covariates, in NMR or pairwise meta‐regression and the
interpretation is natural; graphs were also constructed
using a dataset with a categorical covariate (graphs not
presented).
In conclusion, it is important to consider the contribu-
tion of trials and covariate values to model estimates in
NMR. Graphically displaying the contributions helps to
better understand the data, model, and results, and pre-
vent results from being misinterpreted by review users
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